First-line therapy of osimertinib with chemotherapy in Chinese patients with EGFR mutation–positive non–small cell lung cancer: protocol for a multicenter, prospective, observational study

奥西默替尼 医学 肿瘤科 内科学 肺癌 临床终点 T790米 化疗 无进展生存期 表皮生长因子受体 中止 临床试验 吉非替尼 癌症 埃罗替尼
作者
Bo Zhang,Fangling Ning,Xiaomei Liu,Na Li,Pingfei Wang,Wenxiu Yao,Baohui Han,Qiming Wang,Hua Zhong
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:15
标识
DOI:10.3389/fonc.2025.1625714
摘要

Epidermal growth factor receptor (EGFR) gene mutations are the most common oncogenic-genomic driver in non-small cell lung cancer (NSCLC), with highest prevalence (30%-50%) in Asian patients. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) is the preferred first-line (1L) treatment for patients with NSCLC harboring EGFR-TKI- sensitizing mutations (exon 19del and/or exon 21 L858R). The FLAURA2 study suggested that combining chemotherapy with osimertinib treatment significantly improved progression-free survival (PFS) by approximately 9 months compared with osimertinib monotherapy among patients with EGFR-mutated advanced NSCLC. However, there is a lack of real-world efficacy and safety data for osimertinib in combination with chemotherapy, including the selection of different chemotherapy treatment patterns in real-world settings. This multicenter, prospective, observational study will recruit approximately 700 adult Chinese patients with histologically or cytologically documented non-squamous, stage IIIB/IIIC/IV NSCLC, EGFR sensitive mutation (exon 19del or 21 L858R, either alone or in combination with other EGFR mutations) and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 will be eligible to enroll in the study. Eligible patients will receive osimertinib plus chemotherapy as the 1L therapy based on the physician's medical assessment. The primary endpoint is the median real-world PFS (rwPFS) as assessed by the investigator. Secondary endpoints include treatment pattern and dose intensity of 1L therapy, response rate, duration of response (DoR), overall survival (OS), and safety. Exploratory endpoints include second progression on a subsequent treatment (PFS2), time to treatment discontinuation (TTD), and time to first subsequent treatment (TFST). The central nervous system (CNS) response rate, CNS PFS, subsequent treatment pattern, progression patterns, and the genomic profile in the patients who had disease progression on receiving 1L osimertinib plus chemotherapy. The results of the proposed study aim to contribute evidence on the effectiveness and safety of osimertinib plus chemotherapy with diverse treatment patterns in Chinese patients with advanced NSCLC in real-world settings and support the clinical application of osimertinib-chemotherapy. ClinicalTrials.gov, identifier NCT06376084 (Date of registration: 17-04-2024).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
aaa完成签到,获得积分10
1秒前
XJC完成签到,获得积分10
1秒前
1秒前
赘婿的应助被明天见采纳,获得10
1秒前
2秒前
安静的季节完成签到,获得积分20
3秒前
3秒前
仙仙完成签到,获得积分10
4秒前
4秒前
4秒前
lucky完成签到 ,获得积分10
5秒前
5秒前
丁丁聪完成签到,获得积分10
5秒前
晚风完成签到,获得积分10
6秒前
chope完成签到,获得积分10
6秒前
可爱如音发布了新的文献求助10
6秒前
peace完成签到,获得积分10
6秒前
学术糕手发布了新的文献求助10
6秒前
姚林枝完成签到,获得积分20
7秒前
奔跑的应助被coozrasimon采纳,获得10
7秒前
秋风的应助被阔达的千凝采纳,获得10
8秒前
科研通AI6.4的应助被动听冬寒采纳,获得10
8秒前
8秒前
123发布了新的文献求助10
8秒前
西北一枝花完成签到,获得积分20
9秒前
aaaa的应助被FF采纳,获得30
9秒前
Jotaro发布了新的文献求助10
9秒前
9秒前
shan发布了新的文献求助10
10秒前
10秒前
可爱的函函的应助被慕容平安采纳,获得10
10秒前
10秒前
11秒前
英俊的铭的应助被海纳斯采纳,获得10
11秒前
牂牂完成签到 ,获得积分10
12秒前
12秒前
Lin发布了新的文献求助10
12秒前
Firsterchao的应助被寒冷的断秋采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211